
Tata Trusts' new film reframes periods as a sign of health, not fertility
Tata Trusts has unveiled a new campaign to reframe how India understands menstruation.
Every month, roughly 355 million people in India menstruate. Yet, the subject remains shrouded in silence and shame and is linked to impurity, drawing societal stigma and burdened by age-old beliefs that link periods to fertility and marriage.
In fact, 71 per cent of Indian girls are unaware of menstruation until they experience their first period. For generations, this silence has shaped how menstruation is understood, reducing it to a marker of sexual maturity or the end of childhood, rather than recognising it as a normal biological function.
This campaign flips that narrative, inviting families to recognise menstruation for what it truly is: an indicator of health.
Rooted in deep ethnographic research conducted across rural regions in Jharkhand, Uttar Pradesh and Gujarat, this campaign is anchored in a combination of Social and Behaviour Change Communication (SBCC) across seven states, with a series of cause-driven campaign films and development interventions on-ground that shift the ways in which communities understand, feel and talk about menstruation. Given the universality of the insight, the campaign also has a strong digital presence.
The research explored women's lived realities of restrictions in matters of personal hygiene and healthy menstrual practices. It also uncovered social norms surrounding menstruation, with mothers avoiding the conversation, fearing that their daughters will be seen as 'ready for marriage' – a worry also echoed by Anganwadi Workers.
Men shared limited menstrual awareness, often seeing it through the lens of household disruptions – like how it would affect women's cooking. However, they did show support when prompted, including getting their wives pads and taking them to the doctor when needed.
Shaped by a talented team of behavioural researchers and grassroots and creative partners, this campaign seeks to empower girls to remain children even after their first period, and women to feel confident and well-informed, with nothing left to fear or hide about this natural monthly process.
Divyang Waghela, head – water, sanitation and hygiene (WASH), Tata Trusts, commented, 'Built on the Trusts' rich work in menstrual health and hygiene, and considering how deeply entrenched stigmas remain, we strive to tackle barriers around infrastructure, belief systems, and environments perpetuating them. Through this, girls can view periods as a normal part of health, not something to be hidden away.'
These insights laid the foundation for Tata Trusts' campaign that presents a disruptive, perspective-shifting goal: for periods to be seen as a marker of health and not just sexual maturity.
At the heart of the campaign, running across the series of films as a common thread, is a catchy jingle, 'Maheena Aa gaya' (In this case, Maheena – month – refers to Periods, translating to, 'I've got my periods'). It acts as a cultural bridge, bringing to life everyday scenarios where menstrual symptoms, whether cramps, fatigue, or mood changes, are acknowledged openly by both men and women only as a lakshan (symbol) of health and nothing more. By making these conversations feel comfortable, respectful, and even light-hearted, the campaign aims to de-stigmatize menstruation and create space for empathetic dialogue within families.
Deepshikha Surendran, head of brand and marketing communications, Tata Trusts, said, "'Maheena aa gaya' is more than just flipping a calendar page – it's a symbolic call to action, urging families to rethink what a period means, which we hope will nudge a generational, cultural shift in how menstruation is supported.'
The hero film is supported by films specific to key segments of audiences that shape everyday beliefs around menstruation. In one, a mother lovingly guides her daughter through her first period, explaining that it's simply biology, not a sign of readiness for marriage and that there is nothing to fear or be ashamed of.
Another depicts a husband ensuring his wife's needs during menstruation are met without waiting for her to ask because periods are not just her problem. In another film, a mother-in-law gently supports her daughter-in-law, encouraging her to rest and eat iron-rich food while reminding her, "Yeh siraf sehat ka ek lakshan hai' (this is only about health). These stories, told with warmth and emotional honesty, in real settings, replace fear with familiarity and shame with science. To ensure that the message percolates into conversations at a societal level, another film targeting Asha didis and other health workers, who are the bridge between the community and healthcare system, has been developed.
"We're not asking people to radically shift their thinking – simply, to understand that a period is just a 'lakshan' — a symptom, like hair loss. Capturing this, we created a simple, light film that we shot in people's aangans and homes, with a powerful, memorable song with a hook rooted in Indian pop culture, offering an important reminder: 'Maheene ko sirf sehat se jodo' (link that time of the month – menstruation – to only health),' added Keigan Pinto, the creative director.
Watch the video here:

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
3 hours ago
- Time of India
Pharma, medical device sectors receive right prescription
This is a representative AI image The India-UK FTA is expected to strengthen supply chains for pharma and medical devices sectors, improve access to affordable medicines, and pave the way for collaboration in bulk drugs and joint research. The domestic pharma industry is hopeful exports of generic drugs to UK - currently valued at around $1 billion - will see a boost. Sudarshan Jain, secretary general, Indian Pharmaceutical Alliance, said the pact offers opportunities to supply affordable and quality-assured medicines, contributing to better patient care in the UK. Namit Joshi, chairman of Pharmexcil, added the agreement paves the way for partnerships in bulk drug imports, CDMO, and joint research, strengthening India's competitive edge. The medical devices industry also expects bilateral trade to accelerate. "Earlier, devices imported into UK were duty-free, so tariffs weren't a concern. But regulatory approval costs & timelines were. We had sought UK recognition of Indian CDSCO or QCI certifications to fast-track approvals," said Rajiv Nath, forum coordinator, AiMeD. He highlighted need for stricter Rules of Origin checks to prevent misuse of FTA. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now


Time of India
5 hours ago
- Time of India
Duty relief to boost pharma companies' access to UK drug stores
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The India-UK FTA is expected to give a strong tailwind to India's pharmaceutical and medical devices sectors with tariff relief and smoother regulatory pathways acting as critical drivers, industry experts told agreement will boost exports giving an easier access to the UK market. It is expected to help Indian companies - especially those in generics and biosimilars - to scale their market presence, fast track product approvals, provide a push to cross-border R&D and UK has committed to zero tariff on nearly 99% of Indian pharma exports. While Indian pharma exports to the UK were largely duty free even earlier, the latest agreement formalises the status which brings in long-term clarity to to industry estimates, the pharma market size of the UK stands at about $45 billion and is expected to shoot to $73 billion by 2033. The share of the Indian drugs can see a significant push from the UK's generics segment which is currently pegged at $5 pharmaceutical exports to the UK crossed $910 million in FY24, according to estimates."The agreement strengthens supply chains , enhances access to affordable medicines , and drives Foreign Direct Investment (FDI)," said Namit Joshi, Chairman of Pharmexcil."This partnership paves the way for collaborations in bulk drug imports, CDMO (contract manufacturing), and joint research, empowering India's competitive edge and promoting global partnerships."The pact will open up trade and economic opportunities between the two countries. "The pharma sector will have opportunities to supply quality medicines contributing to better patient care in the UK," said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance."The tariffs relief on generic medicines and key medical devices like surgical instruments and diagnostics under the FTA will enhance the affordability and appeal of Indian products in the UK market," said Manoj Mishra, Partner and Tax Controversy Management Leader, Grant Thornton Bharat. The move significantly boosts the competitiveness of Indian generics and high-quality affordable healthcare solutions, positioning India to scale its footprint in one of Europe's most valuable healthcare markets, said the medical devices sector too the move is expected to open new opportunities, said experts.


The Hindu
5 hours ago
- The Hindu
Doctors stress the need for gender-neutral cervical cancer prevention strategy in India
For years, the human papillomavirus (HPV) vaccine has been closely associated with preventing cervical cancer in women. However, doctors are now pushing for a more inclusive approach, urging that boys too be vaccinated to curb transmission and protect against several other cancers linked to the virus. At the Conquer HPV and Cancer Conclave, an initiative by the Serum Institute of India in Hyderabad on Thursday, doctors underscored the need to reframe HPV as a public health concern rather than solely a women's health issue. 'Why boys? Because they are the carriers. HPV is primarily transmitted through sexual contact. In both Indian and Western statistics, about one in three boys are found to have the virus by the age of 15. While it may not cause immediate symptoms or health issues in boys, it is often passed on to girls, increasing their risk of cervical cancer,' said Dr. M. Surendranath, HoD, Paediatrics, DNB Faculty, Vijay Marie Hospital, Hyderabad. He pointed out that HPV is not limited to cervical cancer. 'It can also lead to penile cancer, anal cancer, and oropharyngeal (throat) cancer in men. Moreover, HPV types 6 and 11 cause genital warts, psychologically distressing, though not cancerous. Australia's decision to vaccinate boys under its national immunisation programme has significantly brought down cases of genital warts,' he said. Silent virus, late consequences One reason for the lack of awareness, doctors say, is that HPV doesn't show symptoms early on. 'It is unlike other viral infections where you get a fever or rash. In the case of HPV, most people don't even realise they've been infected. It can remain dormant in the body for decades and only manifest as cancer years later,' said Dr. D. Leela, consultant gynaecologist, St. Theresa's Hospital and Asvins Hospital, Hyderabad. Screening and prevention: Not just vaccines While vaccination is a crucial step in prevention, doctors highlighted the importance of screening, especially for women aged 30 and above. 'There are three levels of screening. The government-recommended method is VIA (Visual Inspection with Acetic Acid), where simple vinegar is applied to the cervix to check for abnormalities. Then there is the more familiar Pap smear or cytology. And finally, the most sensitive but costly option is the HPV DNA test, which detects the presence of the virus directly,' the doctor added. Vaccine targets and coverage The most commonly used HPV vaccines in India are quadrivalent, targeting types 6, 11, 16, and 18. While 6 and 11 are responsible for genital warts, 16 and 18 account for over 80% of cervical cancer cases. 'As far as genital warts go, they are relatively uncommon in India compared to Western countries. In our clinical experience, they account for about 5 to 10% of cases in gynaecological practice. Many of these patients go to dermatologists instead,' said Dr Surendranath.